Literature DB >> 18263585

Mutation G827R in matriptase causing autosomal recessive ichthyosis with hypotrichosis yields an inactive protease.

Antoine Désilets1, François Béliveau, Guillaume Vandal, François-Olivier McDuff, Pierre Lavigne, Richard Leduc.   

Abstract

Matriptase is a member of the novel family of type II transmembrane serine proteases. It was recently shown that a rare genetic disorder, autosomal recessive ichthyosis with hypotrichosis, is caused by a mutation in the coding region of matriptase. However, the biochemical and functional consequences of the G827R mutation in the catalytic domain of the enzyme have not been reported. Here we expressed the G827R-matriptase mutant in bacterial cells and found that it did not undergo autocatalytic cleavage from its zymogen to its active form as did the wild-type matriptase. Enzymatic activity measurements showed that the G827R mutant was catalytically inactive. When expressed in HEK293 cells, G827R-matriptase remained inactive but was shed as a soluble form, suggesting that another protease cleaved the full-length mature form of matriptase. Molecular modeling based on the crystal structure of matriptase showed that replacing Gly(827) by Arg blocks access to the binding/catalytic cleft of the enzyme thereby preventing autocatalysis of the zymogen form. Our study, thus, provides direct evidence that the G827R mutation in patients with autosomal recessive ichthyosis with hypotrichosis leads to the expression of an inactive protease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18263585      PMCID: PMC2447636          DOI: 10.1074/jbc.M707012200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  Inhibition of human matriptase by eglin c variants.

Authors:  Antoine Désilets; Jean-Michel Longpré; Marie-Eve Beaulieu; Richard Leduc
Journal:  FEBS Lett       Date:  2006-03-20       Impact factor: 4.124

2.  Autosomal recessive ichthyosis with hypotrichosis caused by a mutation in ST14, encoding type II transmembrane serine protease matriptase.

Authors:  Lina Basel-Vanagaite; Revital Attia; Akemi Ishida-Yamamoto; Limor Rainshtein; Dan Ben Amitai; Raziel Lurie; Metsada Pasmanik-Chor; Margarita Indelman; Alex Zvulunov; Shirley Saban; Nurit Magal; Eli Sprecher; Mordechai Shohat
Journal:  Am J Hum Genet       Date:  2007-01-23       Impact factor: 11.025

Review 3.  Matriptase: potent proteolysis on the cell surface.

Authors:  Karin List; Thomas H Bugge; Roman Szabo
Journal:  Mol Med       Date:  2006 Jan-Mar       Impact factor: 6.354

4.  In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma.

Authors:  Diana Förbs; Stefan Thiel; Maria C Stella; Anne Stürzebecher; Andrea Schweinitz; Torsten Steinmetzer; Jörg Stürzebecher; Kerstin Uhland
Journal:  Int J Oncol       Date:  2005-10       Impact factor: 5.650

5.  Evidence for the occurrence of membrane-type serine protease 1/matriptase on the basolateral sides of enterocytes.

Authors:  Satoshi Tsuzuki; Nobuhito Murai; Yuka Miyake; Kuniyo Inouye; Hirofumi Hirayasu; Toshihiko Iwanaga; Tohru Fushiki
Journal:  Biochem J       Date:  2005-06-01       Impact factor: 3.857

6.  HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease.

Authors:  Michael D Oberst; Li-Yuan L Chen; Ken-Ichi Kiyomiya; Cicely A Williams; Ming-Shyue Lee; Michael D Johnson; Robert B Dickson; Chen-Yong Lin
Journal:  Am J Physiol Cell Physiol       Date:  2005-03-30       Impact factor: 4.249

7.  Matriptase inhibition by hepatocyte growth factor activator inhibitor-1 is essential for placental development.

Authors:  R Szabo; A Molinolo; K List; T H Bugge
Journal:  Oncogene       Date:  2006-09-18       Impact factor: 9.867

8.  Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation.

Authors:  Sarah Netzel-Arnett; Brooke M Currie; Roman Szabo; Chen-Yong Lin; Li-Mei Chen; Karl X Chai; Toni M Antalis; Thomas H Bugge; Karin List
Journal:  J Biol Chem       Date:  2006-09-15       Impact factor: 5.157

9.  Phenotypic analysis of mice lacking the Tmprss2-encoded protease.

Authors:  Tom S Kim; Cynthia Heinlein; Robert C Hackman; Peter S Nelson
Journal:  Mol Cell Biol       Date:  2006-02       Impact factor: 4.272

10.  Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation.

Authors:  Karin List; Roman Szabo; Alfredo Molinolo; Virote Sriuranpong; Vivien Redeye; Tricia Murdock; Beth Burke; Boye S Nielsen; J Silvio Gutkind; Thomas H Bugge
Journal:  Genes Dev       Date:  2005-08-15       Impact factor: 11.361

View more
  21 in total

Review 1.  The cutting edge: membrane-anchored serine protease activities in the pericellular microenvironment.

Authors:  Toni M Antalis; Marguerite S Buzza; Kathryn M Hodge; John D Hooper; Sarah Netzel-Arnett
Journal:  Biochem J       Date:  2010-06-15       Impact factor: 3.857

2.  Requirement of the activity of hepatocyte growth factor activator inhibitor type 1 for the extracellular appearance of a transmembrane serine protease matriptase in monkey kidney COS-1 cells.

Authors:  Yuka Miyake; Satoshi Tsuzuki; Makoto Yasumoto; Tohru Fushiki; Kuniyo Inouye
Journal:  Cytotechnology       Date:  2009-08-05       Impact factor: 2.058

3.  Roles of CUB and LDL receptor class A domain repeats of a transmembrane serine protease matriptase in its zymogen activation.

Authors:  Kuniyo Inouye; Marie Tomoishi; Makoto Yasumoto; Yuka Miyake; Kenji Kojima; Satoshi Tsuzuki; Tohru Fushiki
Journal:  J Biochem       Date:  2012-10-03       Impact factor: 3.387

4.  Design and synthesis of potent, selective inhibitors of matriptase.

Authors:  Eloïc Colombo; Antoine Désilets; Dominic Duchêne; Félix Chagnon; Rafael Najmanovich; Richard Leduc; Eric Marsault
Journal:  ACS Med Chem Lett       Date:  2012-04-11       Impact factor: 4.345

5.  Matriptase protects against experimental colitis and promotes intestinal barrier recovery.

Authors:  Sarah Netzel-Arnett; Marguerite S Buzza; Terez Shea-Donohue; Antoine Désilets; Richard Leduc; Alessio Fasano; Thomas H Bugge; Toni M Antalis
Journal:  Inflamm Bowel Dis       Date:  2011-11-13       Impact factor: 5.325

6.  Proteolysis-induced N-terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-terminal domain and recruitment of Src and PKCdelta.

Authors:  Yaowu He; Andreas Wortmann; Les J Burke; Janet C Reid; Mark N Adams; Ibtissam Abdul-Jabbar; James P Quigley; Richard Leduc; Daniel Kirchhofer; John D Hooper
Journal:  J Biol Chem       Date:  2010-06-15       Impact factor: 5.157

7.  Prostasin is required for matriptase activation in intestinal epithelial cells to regulate closure of the paracellular pathway.

Authors:  Marguerite S Buzza; Erik W Martin; Kathryn H Driesbaugh; Antoine Désilets; Richard Leduc; Toni M Antalis
Journal:  J Biol Chem       Date:  2013-02-26       Impact factor: 5.157

8.  Matriptase-deficient mice exhibit ichthyotic skin with a selective shift in skin microbiota.

Authors:  Tiffany C Scharschmidt; Karin List; Elizabeth A Grice; Roman Szabo; Gabriel Renaud; Chyi-Chia R Lee; Tyra G Wolfsberg; Thomas H Bugge; Julia A Segre
Journal:  J Invest Dermatol       Date:  2009-04-23       Impact factor: 8.551

Review 9.  The spatiotemporal control of human matriptase action on its physiological substrates: a case against a direct role for matriptase proteolytic activity in profilaggrin processing and desquamation.

Authors:  Chen-Yong Lin; Jehng-Kang Wang; Michael D Johnson
Journal:  Hum Cell       Date:  2020-04-18       Impact factor: 4.174

10.  The type II transmembrane serine protease matriptase cleaves the amyloid precursor protein and reduces its processing to β-amyloid peptide.

Authors:  Erwan Lanchec; Antoine Désilets; François Béliveau; Anthony Flamier; Shaimaa Mahmoud; Gilbert Bernier; Denis Gris; Richard Leduc; Christine Lavoie
Journal:  J Biol Chem       Date:  2017-10-20       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.